Clearside Biomedical, Inc.
CLSDDrugs in Pipeline
9
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
4mg CLS-TA Suprachoriodal Injection
Uveitis
4 mg CLS-TA Suprachoriodal Injection
Uveitis
CLS-AX
Neovascular Age-related Macular Degeneration
0.8 mg CLS-TA
Uveitis
4 mg CLS-TA
Macular Edema
triamcinolone acetonide (Triesence®)
Uveitis
IVT Aflibercept
Diabetic Macular Edema
Aflibercept
Neovascular Age-related Macular Degeneration
Sham SC
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
4mg CLS-TA Suprachoriodal Injection | Phase 3 | Uveitis | - | - |
4 mg CLS-TA Suprachoriodal Injection | Phase 3 | Uveitis | - | - |
CLS-AX | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
0.8 mg CLS-TA | Phase 2 | Uveitis | - | - |
4 mg CLS-TA | Phase 2 | Macular Edema | - | - |
triamcinolone acetonide (Triesence®) | Phase 2 | Uveitis | - | Patent 2040 |
IVT Aflibercept | Phase 2 | Diabetic Macular Edema | - | - |
Aflibercept | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
Sham SC | Phase 2 | Diabetic Macular Edema | - | - |
Uveitis
4 drugs in this indication
Diabetic Macular Edema
2 drugs in this indication
Neovascular Age-related Macular Degeneration
2 drugs in this indication
Macular Edema
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)